Related Experiment Video

Updated: Jul 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors

Jochen Rössler1, Birgit Geoerger, Melissa Taylor

  • 1Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, 79106 Freiburg, Germany. jochen.roessler@uniklinik-freiburg.de

Current Cancer Drug Targets
|February 22, 2008
PubMed

Insights

Small molecule tyrosine kinase inhibitors target tumor cells and impact tumor growth. This review explores their potential use in treating childhood solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase receptors are key targets in anti-cancer therapies.
  • Small molecule tyrosine kinase inhibitors (TKIs) block intracellular ATP binding sites.
  • TKIs can inhibit tumor cell proliferation, induce apoptosis, and affect migration and angiogenesis.

Purpose of the Study:

  • To review the potential of TKIs in pediatric solid malignancies.
  • To summarize current clinical trial data for TKIs in adult and pediatric cancers.

Main Methods:

  • Literature review of clinical trials and preclinical studies.
  • Analysis of TKI mechanisms of action against tumor and endothelial cells.

Main Results:

  • TKIs show promise by affecting multiple cancer hallmarks.
  • Clinical trials in adults have established TKI efficacy.
  • Emerging data suggests potential in pediatric solid tumors.

Conclusions:

  • Tyrosine kinase inhibitors represent a promising therapeutic avenue for childhood solid malignancies.
  • Further research and clinical trials are warranted to establish TKI efficacy and safety in pediatric oncology.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...